Light-Induced Hydrogel Based on Tumor-Targeting Mesoporous Silica Nanoparticles as a Theranostic Platform for Sustained Cancer Treatment.
Herein, we report a facile fabrication of a polymer (azobenzene and α-cyclodextrin-functionalized hyaluronic acid) and gold nanobipyramids (AuNBs) conjugated mesoporous silica nanoparticles (MSNs) to be used as an injectable drug delivery system for sustained cancer treatment. Because of the specific affinity between the hyaluronic acid (HA) on MSNs and the CD44 antigen overexpressed on tumor cells, the MSNs can selectively attach to tumor cells. The nanocomposite material then exploits thermoresponsive interactions between α-cyclodextrin and azobenzene, and the photothermal properties of gold nanobipyramids, to in situ self-assemble into a hydrogel under near-infrared (NIR) radiation. Upon gelation, the drug (doxorubicin)-loaded MSNs carriers were enclosed in the HA network of the hydrogel, whereas further degradation of the HA in the hydrogel due to the upregulation of hyaluronidase (HAase) around the tumor tissue will result in the release of MSNs from the hydrogel, which can then be taken by tumor cells and deliver their drug to the cell nuclei. This design is able to provide a microenvironment with rich anticancer drugs in, and around, the tumor tissue for time periods long enough to prevent the recrudescence of the disease. The extra efficacy that this strategy affords builds upon the capabilities of conventional therapies.
School of Chemical Engineering and Technology, Institute of Polymer Science in Chemical Engineering, Shanxi Key Laboratory of Energy Chemical Process Intensification, Xi'an Jiao Tong University , Xi'an, 710049, P.R. China.
Xin
X
Chen
Beijing Key Laboratory of Digital Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Department of Prosthodontics, Peking University School and Hospital of Stomatology , Beijing 100081, P.R. China.
Zhongning
Z
Liu
School of Chemistry, Australian Centre for NanoMedicine, and ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of New South Wales , Sydney 2052, Australia.
Stephen G
SG
Parker
Key Laboratory of Biomedical Polymers of Ministry of Education, Department of Chemistry, Wuhan University , Wuhan 430072, P.R. China.
Xiaojin
X
Zhang
School of Chemistry, Australian Centre for NanoMedicine, and ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of New South Wales , Sydney 2052, Australia.
J Justin
JJ
Gooding
School of Chemical Engineering and Technology, Institute of Polymer Science in Chemical Engineering, Shanxi Key Laboratory of Energy Chemical Process Intensification, Xi'an Jiao Tong University , Xi'an, 710049, P.R. China.
Yanyan
Y
Ru
School of Chemical Engineering and Technology, Institute of Polymer Science in Chemical Engineering, Shanxi Key Laboratory of Energy Chemical Process Intensification, Xi'an Jiao Tong University , Xi'an, 710049, P.R. China.
Yuhong
Y
Liu
Beijing Key Laboratory of Digital Stomatology, National Engineering Laboratory for Digital and Material Technology of Stomatology, Department of Prosthodontics, Peking University School and Hospital of Stomatology , Beijing 100081, P.R. China.
Yongsheng
Y
Zhou
D000970:Antineoplastic Agents / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage*; D006046:Gold / Q000737:chemistry; D020100:Hydrogels / Q000737:chemistry*; D008027:Light; D053768:Metal Nanoparticles / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D016062:Porosity; D012822:Silicon Dioxide / Q000737:chemistry / Q000627:therapeutic use*; D000068936:Theranostic Nanomedicine
D000970:Antineoplastic Agents; D020100:Hydrogels; D006046:Gold; D012822:Silicon Dioxide; D004317:Doxorubicin
biodegradable platform; hydrogel-nanoparticles transformation; light responsiveness; mesoporous silica nanocarriers; sustained cancer treatment